secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001493152-24-029775
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack secures $4M convertible note from leading shareholder for CBGM clinical trial
--------------------------------------------------------------------------------

- $4M secured convertible note from John Ballantyne at 8% interest, due in 12 months or upon sale event.
- Note conversion requires stockholder approval; conversion at closing price or auto-convert if stock exceeds $5.
- Three warrants issued: 2.13M shares at $1.875, 1.52M at $2.625, 1.19M at $3.375; exercisable after 12 months for 10 years.
- Directors Shimon Rapp and Andrew Sycoff resigned July 29, no dispute.
- Proceeds to fund first-in-human clinical trial of implantable continuous blood glucose monitor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000149315224029775/0001493152-24-029775-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000149315224029775/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-029775

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer